An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patie
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessme
| Condition(s) | Emphysema, Pulmonary, Emphysema or COPD |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months. |
| Who can participate | Inclusion Criteria: 1. Subject is willing and able to provide informed consent and to participate in the study. 2. Subject is aged ≥ 40 and ≤ 80 years at the time of the ICF signature date. 3. Subject has completed a documented pulmonary rehabilitation (in clinic or home-based) program within 12 months prior to Baseline. 4. Subject has stopped smoking for at least 8 weeks prior to the ICF signature date as confirmed by carboxyhemoglobin or cotinine levels. 5. Subject has a recent HRCT meeting the scan parameter requirements and performed within 3 months of the ICF signature date with the following findings at -910 Hounsfield Units: 1. At least one (1) lobe with segmental emphysema destruction score ≥ 50%. 2. Subject has heterogenous emphysema, defined as difference in emphysema destruction |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Lead sponsor | Pulmonx Corporation |
| Locations | Phoenix, Arizona, United States; Hartford, Connecticut, United States; Orlando, Florida, United States; Chicago, Illinois, United States; Chicago, Illinois, United States; Peoria, Illinois, United States (+30 more sites) |
| Start date | 2024-02-22 |
| NCT ID | NCT06035120 |
| Official listing | https://clinicaltrials.gov/study/NCT06035120 |